WO2020133411A1 - 一种艾氟康唑的制备方法 - Google Patents
一种艾氟康唑的制备方法 Download PDFInfo
- Publication number
- WO2020133411A1 WO2020133411A1 PCT/CN2018/125609 CN2018125609W WO2020133411A1 WO 2020133411 A1 WO2020133411 A1 WO 2020133411A1 CN 2018125609 W CN2018125609 W CN 2018125609W WO 2020133411 A1 WO2020133411 A1 WO 2020133411A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- efluconazole
- add
- reaction
- formula
- compound
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the invention relates to the field of drug synthesis, in particular to a preparation method of efluconazole or its salt.
- Eficonazole (common name: Efinaconazole, trade name: Jublia) is a topical triazole antifungal drug, which is used to treat onychomycosis, has better therapeutic effect and lower side effects.
- Efconazole was developed by Dow Pharmaceuticals and approved by the FDA as an external triazole antifungal drug on June 6, 2014. Clinically, 10% solution is used to treat onychomycosis.
- Patent CN1122598B discloses the use of (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1H-1,2,4-triazol-1-yl)methyl ]
- a method for preparing efluconazole with ethylene oxide and 4-methylene piperidine hydrochloride a large excess of 4-methylene piperidine hydrochloride is usually used in this method, and the reaction takes a long time High temperature heating, high cost, low yield, many by-products, low product purity.
- Patent CN103080100B discloses the preparation method of efluconazole, which adopts basically the same route as patent CN1122598B, but uses different reaction conditions. The change of reaction conditions has improved the reaction yield to a certain extent. Among them, the use of 4-methylene piperidine hydrobromide or hydroiodide has obtained a higher yield, but the use of 4-methylene piperidine The yield of pyridine hydrochloride is still low, and it is easy to produce more impurities, which ultimately affects the purity and yield of efluconazole.
- the present invention provides a method for preparing efluconazole, which method
- the reaction conditions are mild, the product yield is high, the purity is high, the production cost is low, and it is suitable for industrial production.
- the preparation method of efluconazole of the present invention includes the following steps:
- X in the compound of formula B may be Cl, Br or I, preferably Cl.
- the base used in the reaction is selected from one or more of potassium hydroxide, sodium hydroxide, potassium carbonate, and lithium carbonate, preferably potassium hydroxide.
- the reaction solvent used in the reaction is selected from acetonitrile, DMF, DME or DMSO, preferably acetonitrile.
- the bromide used in the reaction is lithium bromide or magnesium bromide, preferably lithium bromide.
- the molar ratio of bromide to the compound of formula A is 1.5-2.5:1, preferably 2.0:1.
- the mass ratio of the reaction solvent to the compound of formula A is 2-5:1, preferably 2:1.
- the molar ratio of the base to the compound of formula A is 1.0 to 1.8:1, preferably 1.3:1.
- the molar ratio of the compound of formula A to the compound of formula B is 1:1.0 to 1:1.8, preferably 1:1.3.
- the reaction can be carried out under heating conditions, the reaction time varies according to the reaction temperature and the solvent used, and the reaction is carried out under normal pressure.
- the temperature of the ring-opening addition reaction is 70-90°C, preferably 85°C; the time of the ring-opening addition reaction is 14-24 hours, preferably 20h.
- the method further includes: after the reaction is completed, post-processing the product to obtain crude efluconazole, wherein the post-treatment does not include a crystallization step.
- the post-treatment is to add ethanol and water to the product, wherein the mass ratio of ethanol and water is 5:6 to 6:6, preferably 5.5:6.
- the method further includes a crystallization step.
- the crystallization step includes: adding the crude afliconazole to a crystallization solvent, stirring and crystallizing, and filtering to obtain pure afliconazole.
- the crystallization temperature is 0-25°C, preferably 0-10°C, more preferably 5-8°C.
- the time for stirring and crystallization is 2-15 hours, preferably 4-14 hours.
- the crystallization solvent used in the crystallization step may be n-heptane, isopropyl ether, acetonitrile/water, acetone/water, ethanol/water, ethanol/acetonitrile/water, ether/n-hex
- the alkane, or cyclohexane is preferably cyclohexane.
- the prepared efluconazole can form a salt with an acid.
- the prepared efluconazole can form methanesulfonate with methanesulfonic acid, and p-toluenesulfonic acid can form p-toluenesulfonate.
- FIG. 1 is a 1 H-NMR chart of the pure efluconazole prepared in Example 2 of the present application.
- FIG. 2 is a 13 C-NMR chart of the pure efluconazole prepared in Example 2 of the present application.
- Ethylene oxide is prepared by the method of Example 2 in patent CN106608867A;
- 4-methylene piperidine hydrochloride can be prepared by reacting 4-methylene piperidine with hydrochloric acid, for example, 4-methylene Piperidine hydrochloride can be prepared according to the following reaction.
- the filtrate is concentrated under reduced pressure until it does not slip (in the form of oil), add ethanol (825g), filter, and the filtrate is cooled to 0-10°C , 900g of purified water was added dropwise. After the dropwise addition, the mixture was kept under heat and stirred for 2 hours, filtered with suction, and the filter cake was vacuum dried at 47° C. to obtain 167.0 g of crude off-white solid efluconazole with a yield of 80.27%. The purity is 99.25%.
- the mass ratio of added ethanol and water is 5:6 to 6:6, preferably 5.5:6.
- the following further provides an example in which the mass ratio of adding ethanol to water in the post-treatment for preparing crude efluconazole is 4:6 to 6:6.
- the purification method of cyclohexane can make the total impurities of the product less than 0.10%, the HPLC purity is greater than 99.90%, and the purification yield is above 80%.
- the purification methods of other solvents can only control the total impurity of the product to be less than 0.5%.
- the purification yield of the ethanol/water system is between 75% and 97%, and the HPLC purity is between 99.5 and 99.9%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Description
Claims (16)
- 根据权利要求1所述的方法,其中反应中所用的碱选自氢氧化钾、氢氧化钠、碳酸钾、碳酸锂中的一种或多种,优选为氢氧化钾。
- 根据权利要求1或2所述的方法,其中反应中所用的反应溶剂选自乙腈、DMF、DME或DMSO,优选为乙腈。
- 根据权利要求1-3中任一项所述的方法,其中反应中所用的溴化物为溴化锂或溴化镁,优选为溴化锂。
- 根据权利要求1-4中任一项所述的方法,其中所述溴化物与所述式A化合物的摩尔比为1.5~2.5:1,优选为2.0:1。
- 根据权利要求1-5中任一项所述的方法,其中所述反应溶剂与所述式A化合物的质量比为2~5:1,优选为2:1。
- 根据权利要求1-6中任一项所述的方法,其中所述碱与所述式A化合物的摩尔比为1.0~1.8:1,优选为1.3:1。
- 根据权利要求1-7中任一项所述的方法,其中所述式A化合物与所述式B化合物的摩尔比为1:1.0~1:1.8,优选为1:1.3。
- 根据权利要求1-8中任一项所述的方法,其中所述开环加成反应的温度为70~90℃,优选为85℃;所述开环加成反应的时间为14~24h,优选为20h。
- 根据权利要求1-9中任一项所述的方法,所述方法还包括:在反应结束后,对产物进行后处理以获得艾氟康唑粗品,其中所述后处理不包括结晶步骤。
- 根据权利要求10所述的方法,其中所述后处理为向产物中加入乙醇和水,其中乙醇和水的质量比为5:6~6:6,优选为5.5:6。
- 根据权利要求1-11中任一项所述的方法,所述方法还包括结晶步骤。
- 根据权利要求12所述的方法,其中所述结晶步骤包括:将艾氟康唑粗品加入结晶溶剂中,搅拌析晶,过滤,得艾氟康唑纯品。
- 根据权利要求13所述的方法,其中,在所述结晶步骤中,析晶温度为0~25℃,优选为0-10℃,更优选5-8℃;搅拌析晶的时间为2-15小时,优选为4-14小时。
- 根据权利要求12所述的方法,其中所述结晶步骤中使用的结晶溶剂选自正庚烷、异丙醚、乙腈/水、丙酮/水、乙醇/水、乙醇/乙腈/水、乙醚/正己烷,或环己烷,优选为环己烷。
- 根据权利要求1-15中任一项所述的方法,将得到的式I化合物与酸形成盐。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18944314.6A EP3885341A4 (en) | 2018-12-29 | 2018-12-29 | PROCESS FOR MANUFACTURE OF EFINACONAZOLE |
US17/281,544 US20210363129A1 (en) | 2018-12-29 | 2018-12-29 | Preparation method for efinaconazole |
PCT/CN2018/125609 WO2020133411A1 (zh) | 2018-12-29 | 2018-12-29 | 一种艾氟康唑的制备方法 |
JP2021517631A JP2022515696A (ja) | 2018-12-29 | 2018-12-29 | エフィナコナゾールの調製方法 |
KR1020217017538A KR102622061B1 (ko) | 2018-12-29 | 2018-12-29 | 에피나코나졸의 제조 방법 |
CN201880097322.9A CN112805271A (zh) | 2018-12-29 | 2018-12-29 | 一种艾氟康唑的制备方法 |
CA3115742A CA3115742C (en) | 2018-12-29 | 2018-12-29 | Preparation method for efinaconazole |
IL282108A IL282108A (en) | 2018-12-29 | 2021-04-06 | A method for preparing epiconazole |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/125609 WO2020133411A1 (zh) | 2018-12-29 | 2018-12-29 | 一种艾氟康唑的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020133411A1 true WO2020133411A1 (zh) | 2020-07-02 |
Family
ID=71128956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/125609 WO2020133411A1 (zh) | 2018-12-29 | 2018-12-29 | 一种艾氟康唑的制备方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210363129A1 (zh) |
EP (1) | EP3885341A4 (zh) |
JP (1) | JP2022515696A (zh) |
KR (1) | KR102622061B1 (zh) |
CN (1) | CN112805271A (zh) |
CA (1) | CA3115742C (zh) |
IL (1) | IL282108A (zh) |
WO (1) | WO2020133411A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113929660A (zh) * | 2021-10-18 | 2022-01-14 | 深圳市海滨制药有限公司 | 一种环氧乙烷衍生物开环方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1225980A (zh) | 1998-01-13 | 1999-08-18 | 株式会社丰田自动织机制作所 | 可变排量压缩机 |
CN103080100A (zh) | 2010-08-31 | 2013-05-01 | 科研制药株式会社 | 1-三唑-2-丁醇衍生物的制造方法 |
CN106565672A (zh) * | 2015-10-08 | 2017-04-19 | 中美华世通生物医药科技(武汉)有限公司 | 制备艾氟康唑的方法 |
CN106608867A (zh) | 2015-10-23 | 2017-05-03 | 山东威智医药工业有限公司 | 艾氟康唑及其中间体的制备方法、其中间体 |
CN106928186A (zh) * | 2015-12-29 | 2017-07-07 | 中美华世通生物医药科技(武汉)有限公司 | 化合物及其制备方法和用途 |
CN107778283A (zh) * | 2016-08-26 | 2018-03-09 | 山东特珐曼药业有限公司 | 一种艾氟康唑的制备方法和其晶型m |
CN108276381A (zh) * | 2017-01-06 | 2018-07-13 | 上海和博药物研究有限公司 | 一种艾氟康唑的合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3437695B2 (ja) * | 1993-05-10 | 2003-08-18 | 科研製薬株式会社 | アゾリルアミン誘導体 |
ATE161257T1 (de) * | 1993-05-10 | 1998-01-15 | Kaken Pharma Co Ltd | Azolylamin-derivat |
US20180002310A1 (en) * | 2015-01-20 | 2018-01-04 | Perrigo Api Ltd. | Crystalline forms of efinaconazole |
US10125115B2 (en) * | 2015-06-04 | 2018-11-13 | Glenmark Pharmaceuticals Limited | Process for the preparation of efinaconazole |
EP3112360A1 (en) * | 2015-06-29 | 2017-01-04 | Dipharma Francis S.r.l. | Process for the preparation of efinaconazole |
CN107759565B (zh) * | 2016-08-15 | 2020-10-23 | 苏州旺山旺水生物医药有限公司 | 一种1-三唑-2-丁醇衍生物的制备方法 |
-
2018
- 2018-12-29 EP EP18944314.6A patent/EP3885341A4/en active Pending
- 2018-12-29 CA CA3115742A patent/CA3115742C/en active Active
- 2018-12-29 WO PCT/CN2018/125609 patent/WO2020133411A1/zh unknown
- 2018-12-29 JP JP2021517631A patent/JP2022515696A/ja active Pending
- 2018-12-29 KR KR1020217017538A patent/KR102622061B1/ko active IP Right Grant
- 2018-12-29 CN CN201880097322.9A patent/CN112805271A/zh active Pending
- 2018-12-29 US US17/281,544 patent/US20210363129A1/en active Pending
-
2021
- 2021-04-06 IL IL282108A patent/IL282108A/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1225980A (zh) | 1998-01-13 | 1999-08-18 | 株式会社丰田自动织机制作所 | 可变排量压缩机 |
CN103080100A (zh) | 2010-08-31 | 2013-05-01 | 科研制药株式会社 | 1-三唑-2-丁醇衍生物的制造方法 |
CN106565672A (zh) * | 2015-10-08 | 2017-04-19 | 中美华世通生物医药科技(武汉)有限公司 | 制备艾氟康唑的方法 |
CN106608867A (zh) | 2015-10-23 | 2017-05-03 | 山东威智医药工业有限公司 | 艾氟康唑及其中间体的制备方法、其中间体 |
CN106928186A (zh) * | 2015-12-29 | 2017-07-07 | 中美华世通生物医药科技(武汉)有限公司 | 化合物及其制备方法和用途 |
CN107778283A (zh) * | 2016-08-26 | 2018-03-09 | 山东特珐曼药业有限公司 | 一种艾氟康唑的制备方法和其晶型m |
CN108276381A (zh) * | 2017-01-06 | 2018-07-13 | 上海和博药物研究有限公司 | 一种艾氟康唑的合成方法 |
Non-Patent Citations (2)
Title |
---|
CAS, no. 164650-44-6 |
KEIJI TAMURA ET AL.: "reports in a non-patent literature", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 79, no. 7, 2014, pages 3272 - 3278 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113929660A (zh) * | 2021-10-18 | 2022-01-14 | 深圳市海滨制药有限公司 | 一种环氧乙烷衍生物开环方法 |
Also Published As
Publication number | Publication date |
---|---|
CA3115742C (en) | 2023-10-03 |
EP3885341A4 (en) | 2022-08-10 |
CN112805271A (zh) | 2021-05-14 |
JP2022515696A (ja) | 2022-02-22 |
CA3115742A1 (en) | 2020-07-02 |
US20210363129A1 (en) | 2021-11-25 |
EP3885341A1 (en) | 2021-09-29 |
IL282108A (en) | 2021-05-31 |
KR20210090225A (ko) | 2021-07-19 |
KR102622061B1 (ko) | 2024-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20190133725A (ko) | 6-(시클로프로판아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 제조 방법 | |
TW202235415A (zh) | 奧美卡替莫卡必爾的合成 | |
WO2017108010A1 (zh) | 一种伏立康唑中间体及伏立康唑的合成方法 | |
US20210387952A1 (en) | Solid state forms of daprodustat and process for preparation thereof | |
WO2016016766A2 (en) | A process for the preparation of isavuconazonium or its salt thereof | |
JP2021501127A5 (zh) | ||
WO2021057082A1 (zh) | 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途 | |
EP4153551A1 (en) | Solid state forms of tapinarof | |
WO2020133411A1 (zh) | 一种艾氟康唑的制备方法 | |
KR102233456B1 (ko) | 4-메톡시피롤 유도체의 중간체 제조 방법 | |
JP2004520446A (ja) | ロサルタンカリウムの結晶化方法 | |
JP2017036262A (ja) | ピペリジン化合物の製造方法 | |
US8039631B2 (en) | Process for preparing crystalline form A of Lansoprazole | |
JP4097291B2 (ja) | 置換バリンアミド誘導体の製造方法 | |
CN115557876A (zh) | 一种用于治疗消化性溃疡的3-芳环基磺酰基-1-n-杂吡咯衍生物、其制备方法和用途 | |
WO2023173717A1 (zh) | 作为合成泊沙康唑的中间体化合物的制备方法及其制备的中间化合物 | |
WO2008090565A1 (en) | Novel thermodynamically stable polymorphic form-l of letrozole | |
EP3853217B1 (en) | Crystalline form of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide | |
JP2873599B2 (ja) | 新規ベンゾフラン誘導体、尿酸排泄剤及びその製法 | |
CN110563643A (zh) | 一种(5-溴-3-甲基-吡啶-2-基)-甲胺的合成方法 | |
US4052409A (en) | Disubstituted triphenylmethylimidazoles | |
US3804836A (en) | N-phenyl-n'-dialkylphosphinylalkyl-piperazines | |
CN113698310B (zh) | 一种恩杂鲁胺双酯中间体的制备方法 | |
JP6336166B2 (ja) | イミダフェナシンの新規中間体、その製造方法及びそれを用いたイミダフェナシンの製造方法 | |
KR20070089487A (ko) | 안지오텐신 ⅱ 길항제의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18944314 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021517631 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3115742 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20217017538 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018944314 Country of ref document: EP Effective date: 20210621 |